Rob Magin joined the Mark Foundation in May 2021. He came to the Foundation from the Dana-Farber Cancer Institute in Boston, where he conducted his post-doctoral research as part of a collaborative team developing first-in-class inhibitors against deubiquitinating enzymes. Prior to this, Rob received his PhD in Biochemistry and Molecular Biophysics from the University of Pennsylvania, and a BA in Biology from Northwestern University, where his research projects integrated biochemistry, structural biology, and chemical biology.
